Consensus Telomerase Vaccine for Cross-Species Tumor Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccination strategies targeting telomerase, whether in humans or veterinary applications, face limitations such as HLA-restriction and lack of universality, leading to limited clinical impact on telomerase-expressing tumors.

Innovation Solution

Development of a chimeric vaccine using a consensus sequence of human and dog telomerase (conTRT) combined with immunomodulating sequences, administered via electroporation, to enhance immune response and cross-reactivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If HLA-restricted vaccines are used to target telomerase, then specific immune response is induced, but universality across different patients and species is limited

Engineering Contradiction:

Improveuniversality of vaccine responseVSAvoidimmune response effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent creates a consensus sequence vaccine that is universally applicable across different HLA types and species. The ConTRT antigen sequence is designed to be recognized by multiple HLA alleles (HLA-A*02:01, HLA-A*24:02, HLA-B*07:02) and works in both human and canine systems, eliminating the need for HLA-matched personalized vaccines while maintaining reliable immune response induction.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If single-species telomerase vaccines are used, then species-specific immune response is achieved, but cross-species applicability is lost

Engineering Contradiction:

Improvecross-species vaccine applicabilityVSAvoidimmune response magnitude

Core Design Contradiction:

Adaptability or versatilityVSQuantity of substance

Solution Approach 1:

The patent merges human and canine telomerase sequences to create a consensus sequence (ConTRT) that combines the most conserved regions from both species. This fusion approach allows a single vaccine to elicit immune responses against telomerase in both human and canine systems, achieving cross-species applicability while maintaining sufficient immune response magnitude through the inclusion of immunodominant epitopes from both sources.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If conventional vaccination strategies are used, then preventive immunity is established, but therapeutic effect on existing tumors is insufficient

Engineering Contradiction:

Improvetherapeutic vaccine effectivenessVSAvoidvaccine formulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs a composite vaccine formulation that combines the ConTRT antigen sequence with adjuvants and delivery systems optimized for therapeutic intervention. This composite approach enhances the vaccine's ability to treat existing tumors by incorporating multiple functional components that work synergistically to boost immunogenicity and therapeutic efficacy without requiring overly complex multi-component formulations.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12622955B2Consensus sequence of the antigen telomerase and the use thereof in preventive and therapeutic vaccination

Publication Date: 2026.05.12 EVVIVAX SRL

AI summary

A consensus sequence of the antigen telomerase (ConTRt) can be generated and used in preventive and therapeutic vaccination. The consensus sequence of telomerase was generated by the fusion of two sequences, one belonging to human telomerase (hTERT) and the other to dog telomerase (dTERT), with the aim of developing an effective vaccine for the treatment of tumors expressing both human and dog telomerase, hence in both the human and veterinary sectors.